全文获取类型
收费全文 | 179篇 |
免费 | 34篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 4篇 |
基础医学 | 19篇 |
临床医学 | 36篇 |
内科学 | 95篇 |
神经病学 | 3篇 |
外科学 | 10篇 |
综合类 | 5篇 |
预防医学 | 17篇 |
药学 | 1篇 |
中国医学 | 4篇 |
肿瘤学 | 18篇 |
出版年
2023年 | 3篇 |
2022年 | 1篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 4篇 |
2018年 | 8篇 |
2017年 | 5篇 |
2016年 | 5篇 |
2015年 | 4篇 |
2014年 | 3篇 |
2013年 | 8篇 |
2012年 | 9篇 |
2011年 | 16篇 |
2010年 | 3篇 |
2009年 | 1篇 |
2008年 | 13篇 |
2007年 | 20篇 |
2006年 | 11篇 |
2005年 | 13篇 |
2004年 | 16篇 |
2003年 | 24篇 |
2002年 | 16篇 |
2001年 | 8篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1998年 | 3篇 |
1997年 | 1篇 |
1996年 | 5篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1988年 | 1篇 |
1977年 | 1篇 |
1960年 | 1篇 |
排序方式: 共有213条查询结果,搜索用时 359 毫秒
11.
十二指肠球部溃疡属于中医胃脘痛的范畴。按中医辨证分型适于黄芪建中汤治疗的有3种类型,即脾胃虚寒型、脾胃虚弱型、气虚血瘀型。通过用黄芪建中汤加减治疗45例十二指肠球部溃疡病患者,其中临床治愈14例,占31.1%;好转者27例,占60%;无效4例,占8.9%。总有效率为91.1%。 相似文献
12.
Keith Wheatley Alan K. Burnett Anthony H. Goldstone Richard G. Gray Ian M. Hann Christine J. Harrison John K. H. Rees Richard F. Stevens & Helen Walker on behalf of the United Kingdom Medical Research Council''s Adult Childhood Leukaemia Working Parties 《British journal of haematology》1999,107(1):69-79
Data on 1711 patients, aged up to 55 years, in the MRC AML 10 trial were used to create a prognostic index for use in risk-directed therapy decision making for younger patients with acute myeloid leukaemia (AML). Two parameters, response after course 1 and cytogenetics, were strongly predictive of outcome. For patients with complete remission, partial remission and resistant disease, 5-year survival from the start of course 2 was 53%, 44% and 22% and relapse rates were 46%, 48% and 69% respectively, and for patients with favourable, intermediate and adverse karyotypic abnormalities, survival was 72%, 43% and 17% and relapse rates were 34%, 51% and 75% respectively (all P < 0.0001). Patients with FAB type M3 but no cytogenetic t(15;17) also had a low relapse rate (29%). These three factors were combined to give three risk groups: good (favourable karyotype or M3, irrespective of response status or presence of additional abnormalities), standard (neither good nor poor), poor (adverse karyotype or resistant disease, and no good-risk features). Survival for these three groups was 70%, 48% and 15% respectively and relapse rates were 33%. 50% and 78% (both P < 0.0001). The index is simple (based on just three parameters), robust (derived from 1711 patients), highly discriminatory (55% survival difference between good and poor risk) and validated, so can be applied in the clinical setting to assist with therapeutic decisions as in the current AML 12 trial. 相似文献
13.
John?L?Moran Patricia?J?Solomon the Adult Database Management Committee of the Australian New Zealand Intensive Care Society 《BMC medical research methodology》2010,10(1):32
Background
Controversy has attended the relationship between risk-adjusted mortality and process-of-care. There would be advantage in the establishment, at the data-base level, of global quantitative indices subsuming the diversity of process-of-care. 相似文献14.
15.
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study 总被引:2,自引:0,他引:2
Schifitto G Navia BA Yiannoutsos CT Marra CM Chang L Ernst T Jarvik JG Miller EN Singer EJ Ellis RJ Kolson DL Simpson D Nath A Berger J Shriver SL Millar LL Colquhoun D Lenkinski R Gonzalez RG Lipton SA;Adult AIDS Clinical Trial Group 《AIDS (London, England)》2007,21(14):1877-1886
OBJECTIVE: To assess the safety and efficacy of memantine, an uncompetitive antagonist of the N-methyl-D-aspartate receptor as treatment of HIV-associated cognitive impairment. METHODS: This was a Phase II randomized, double-blind, placebo-controlled, multicenter trial within the Adult AIDS Clinical Trials Group. One-hundred and forty HIV-infected adults with mild to severe AIDS dementia complex receiving stable antiretroviral therapy were enrolled. Memantine was initiated at 10 mg daily escalated to 40 mg daily, or up to the maximum tolerated dose and continued for 16 weeks (primary evaluation visit) followed by a 4-week washout period and re-evaluation at week 20. Changes in cognitive performance were measured as percent change from baseline to week 16 in the average of eight neuropsychological test scores (NPZ-8). Brain metabolism was measured by magnetic resonance spectroscopy in a subgroup of subjects. RESULTS: Sixty-one percent of subjects in the memantine group and 85% in the placebo group reached the 40 mg dose while the reported adverse experiences between the two groups were similar. There were no significant improvements in neuropsychological performance over 16 weeks; however, memantine was associated with a significant increase at week 16 in the N-acetyl aspartate to creatine ratio, in the frontal white matter (P = 0.040) and parietal cortex (P = 0.023). CONCLUSIONS: Memantine was safe and tolerated by HIV-infected subjects with cognitive impairment. Although we observed no significant differences in cognitive performance, the magnetic resonance spectroscopy data suggest that memantine may ameliorate neuronal metabolism, an important step to stabilizing or preventing neuronal injury. These results underscore the need for longer studies to assess the full potential of neuroprotective agents. 相似文献
16.
Usui N Takeshita A Nakaseko C Dobashi N Fujita H Kiyoi H Kobayashi Y Sakura T Yahagi Y Shigeno K Ohwada C Miyazaki Y Ohtake S Miyawaki S Naoe T Ohnishi K;Japan Adult Leukemia Study Group 《Cancer science》2011,102(7):1358-1365
In order to investigate better molecular-target therapy for acute myeloid leukemia (AML), we conducted a phase I trial of a combination of gemtuzumab ozogamicin (GO) with conventional chemotherapy. Between January 2007 and December 2009, a total of 19 adult Japanese patients with relapsed or refractory CD33-positive AML (excluding acute promyelocytic leukemia) were enrolled. All registered patients received a standard dose of cytarabine (Ara-C) (100 mg/m(2) × 7 days), combined with either idarubicin (IDR) (10-12 mg/m(2) × 3 days) or daunorubicin (DNR) (50 mg/m(2) × 3-5 days), and then GO (3-5 mg/m(2) ), which was administered 1 day after the last infusion of IDR (IAG regimen) or DNR (DAG regimen). While doses of both GO and IDR and the administration period of only DNR were increased, the dose-limiting toxicity (DLT) was assessed. Among 19 patients (nine in the IAG regimen, 10 in the DAG regimen), the median age was 59 years (range 33-64), and the relapsed/refractory ratio was 13/6. In the therapy using 3 mg/m(2) GO in the IAG or DAG regimen, grade 3/4 leukopenia and neutropenia were observed in all patients, but none had grade 3/4 non-hematological toxicities, except febrile neutropenia. Three patients in the IAG regimen who were administered 5 mg/m(2) GO showed DLT. No patients had veno-occlusive disease or sinusoidal obstructive syndrome. In conclusion, 3 mg/m(2) GO combined with Ara-C and IDR or DNR can be safely administered, and phase II trials should be conducted to investigate the clinical efficacy of the combination therapy. 相似文献
17.
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity 总被引:1,自引:1,他引:0 下载免费PDF全文
Ferrari S Scheiflinger F Rieger M Mudde G Wolf M Coppo P Girma JP Azoulay E Brun-Buisson C Fakhouri F Mira JP Oksenhendler E Poullin P Rondeau E Schleinitz N Schlemmer B Teboul JL Vanhille P Vernant JP Meyer D Veyradier A;French Clinical Biological Network on Adult Thrombotic Microangiopathies 《Blood》2007,109(7):2815-2822
To study both the pathophysiologic and the prognostic value of ADAMTS13 in thrombotic microangiopathies (TMAs), we enrolled a cohort of 35 adult patients combining a first acute episode of TMA, an undetectable (below 5%) ADAMTS13 activity in plasma, and no clinical background such as sepsis, cancer, HIV, and transplantation. All patients were treated by steroids and plasma exchange, and an 18-month follow-up was scheduled. Remission was obtained in 32 patients (91.4%), and 3 patients died (8.6%) after the first attack. At presentation, ADAMTS13 antigen was decreased in 32 patients (91.4%), an ADAMTS13 inhibitor was detectable in 31 patients (89%), and an anti-ADAMTS13 IgG/IgM/IgA was present in 33 patients (94%). The 3 decedent patients were characterized by the association of several anti-ADAMTS13 Ig isotypes, including very high IgA titers, while mortality was independent of the ADAMTS13 inhibitor titer. In survivors, ADAMTS13 activity in remission increased to levels above 15% in 19 patients (59%) but remained undetectable in 13 patients (41%). Six patients relapsed either once or twice (19%) during the follow-up. High levels of inhibitory anti-ADAMTS13 IgG at presentation were associated with the persistence of an undetectable ADAMTS13 activity in remission, the latter being predictive for relapses within an 18-month delay. 相似文献
18.
de Labarthe A Rousselot P Huguet-Rigal F Delabesse E Witz F Maury S Réa D Cayuela JM Vekemans MC Reman O Buzyn A Pigneux A Escoffre M Chalandon Y MacIntyre E Lhéritier V Vernant JP Thomas X Ifrah N Dombret H;Group for Research on Adult Acute Lymphoblastic Leukemia 《Blood》2007,109(4):1408-1413
The combination of imatinib with chemotherapy has been recently reported as very promising in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL). Imatinib was then continuously administered until stem cell transplantation (SCT). Overall, complete remission (CR) and BCR-ABL real-time quantitative polymerase chain reaction (RQ-PCR) negativity rates were 96% and 29%, respectively. All of the 22 CR patients (100%) with a donor actually received allogeneic SCT in first CR. At 18 months, the estimated cumulative incidence of relapse, disease-free survival, and overall survival were 30%, 51%, and 65%, respectively. These 3 end points compared very favorably with results obtained in the pre-imatinib LALA-94 trial. This study confirms the value of the combined approach and encourages prospective trials to define the optimal chemotherapy that has to be combined with imatinib and to carefully reevaluate the place of allogeneic SCT in this new context. 相似文献
19.
Stow PJ Pilcher D Wilson J George C Bailey M Higlett T Bellomo R Hart GK;Australian & New Zealand Intensive Care Society Adult Patient Database Management Committee 《Thorax》2007,62(10):842-847
BACKGROUND: There is limited information on changes in the epidemiology and outcome of patients with asthma admitted to intensive care units (ICUs) in the last decade. A database sampling intensive care activity in hospitals throughout Australia offers the opportunity to examine these changes. METHODS: The Australian and New Zealand Intensive Care Society Adult Patient Database was examined for all patients with asthma admitted to ICUs from 1996 to 2003. Demographic, physiological and outcome information was obtained and analysed from 22 hospitals which had submitted data continuously over this period. RESULTS: ICU admissions with the primary diagnosis of asthma represented 1899 (1.5%) of 126 906 admissions during the 8-year period. 36.1% received mechanical ventilation during the first 24 h. The overall incidence of admission to ICU fell from 1.9% in 1996 to 1.1% in 2003 (p<0.001). Overall hospital mortality was 3.2%. There was a significant decline in mortality from a peak of 4.7% in 1997 to 1.1% in 2003 (p = 0.014). This was despite increasing severity of illness (as evidenced by an increasing predicted risk of death derived from the APACHE II score) over the 8-year period (p = 0.002). CONCLUSIONS: There has been a significant decline in the incidence of asthma requiring ICU admission between 1996 and 2003 among units sampled by the Australian and New Zealand Intensive Care Society Adult Patient Database. The mortality of these patients has also decreased over time and is lower than reported in other studies. 相似文献
20.